利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.047 秒)

    Anti-mesothelin antibodies
    41.
    发明授权
    Anti-mesothelin antibodies 有权
    抗间皮素抗体

    公开(公告)号：US07592426B2

    公开(公告)日：2009-09-22

    申请号：US11373546

    申请日：2006-03-09

    申请人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    发明人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    IPC分类号： C12P21/08 ,  A61K38/00

    CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77

    摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

    摘要翻译： 本发明涉及单克隆和多克隆抗体的使用，其特异性结合并被间皮素阳性细胞内化，并且还诱导免疫效应子活性如抗体依赖性细胞毒性。 该抗体可用于特异性递送表达间皮素的药物学药剂，以及引发免疫效应物特异性对肿瘤细胞和前体的活性。 本发明还涉及表达单克隆抗体，多克隆抗体，抗体衍生物如人，人源化和嵌合单克隆抗体的细胞，抗体片段，表达单克隆抗体的哺乳动物细胞，衍生物和片段，以及使用 抗体，衍生物和片段。

    Whole Genome Evolution Technology Applied To Improve Protein And Antibody Yields By Cells
    43.
    发明申请
    Whole Genome Evolution Technology Applied To Improve Protein And Antibody Yields By Cells 审中-公开
    全基因组进化技术应用于提高细胞的蛋白质和抗体产量

    公开(公告)号：US20080131427A1

    公开(公告)日：2008-06-05

    申请号：US11735707

    申请日：2007-04-16

    申请人： J. Bradford Kline ,  Qimin Chao ,  Philip M. Sass ,  Luigi Grasso ,  Nicholas C. Nicolaides

    发明人： J. Bradford Kline ,  Qimin Chao ,  Philip M. Sass ,  Luigi Grasso ,  Nicholas C. Nicolaides

    IPC分类号： A61K39/395 ,  C12N5/06

    CPC分类号： C12N15/01 ,  C12N15/1024 ,  C12N15/1079

    摘要： Whole Genome Evolution Technology can be considered a broad tool for supporting the needs for scaleable manufacturing of therapeutic antibodies. Its random nature and in vivo mode of action separate this process from other complementary technologies, thus providing alternative solutions to improve a host cell's manufacturing performance. The speed with which a pre-existing production strain can be optimized makes this process suitable for satisfying the current need for rapid cell line optimization to produce faster growing cells exhibiting high titers of antibody at the preclinical, clinical or commercialization stage.

    摘要翻译： 全基因组进化技术可以被认为是支持可扩展制造治疗性抗体需求的广泛工具。 其随机性质和体内作用模式将该过程与其他互补技术分开，从而提供替代解决方案来改善宿主细胞的制造性能。 可以优化预先存在的生产菌株的速度使得该方法适合于满足目前对快速细胞系优化的需要，以在临床前，临床或商业化阶段产生更高生长细胞，其表现出高滴度抗体。

    ENGINEERED HUMAN ENDOSIALIN-EXPRESSING RODENTS
    46.
    发明申请
    ENGINEERED HUMAN ENDOSIALIN-EXPRESSING RODENTS 审中-公开
    工程人体内分泌表达物

    公开(公告)号：US20130305396A1

    公开(公告)日：2013-11-14

    申请号：US13876232

    申请日：2011-09-28

    申请人： Luigi Grasso ,  Jian Min Lin ,  Yuhong Zhou ,  Brian E. Tomkowicz ,  Nicholas C. Nicolaides ,  Philip M. Sass

    发明人： Luigi Grasso ,  Jian Min Lin ,  Yuhong Zhou ,  Brian E. Tomkowicz ,  Nicholas C. Nicolaides ,  Philip M. Sass

    IPC分类号： A61K49/00

    CPC分类号： A61K49/0008 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0368 ,  A01K2267/0375 ,  C07K14/7056 ,  C07K14/70596 ,  G01N33/5088

    摘要： Provided herein are rodents that express the human endosialin gene. In preferred embodiments, the rodent is a mouse. Preferably, the human endosialin gene is integrated into the native or endogenous endosialin gene locus. More preferably, the host rodent is null for the endogenous endosialin gene product. The human endosialin gene is preferably expressed in a similar development and disease response pattern as that of the native endosialin gene product in parental or wild type rodents. This feature makes these rodents useful for studying the effects of test agents to positively or negatively affect endosialin biology for therapeutic use. Use of human endosialin expressing rodents lacking native endosialin gene product (HUE rodents) is proposed as a strategy for developing agents that can positively or negatively affect the endosialin pathway and also serve as a screening tool to identify those agents that may be useful as human therapies.

    摘要翻译： 本文提供表达人内皮唾液酸基因的啮齿动物。 在优选的实施方案中，啮齿动物是小鼠。 优选地，人内皮唾液酸蛋白基因整合到天然或内源性内唾液酸基因座。 更优选地，宿主啮齿动物对于内源性内唾液酸基因产物是无效的。 人内皮唾液酸蛋白基因优选以与亲本或野生型啮齿动物中的天然唾液酸内切酶基因产物相似的发育和疾病应答模式表达。 该特征使得这些啮齿动物可用于研究试验剂对用于治疗用途的唾液酸生物学的正面或负面影响的影响。 提出缺乏天然唾液酸内切酶基因产物（HUE啮齿类动物）的人类内皮糖蛋白表达啮齿动物的使用作为可以对内皮唾液酸途径有正面或负面影响的发育剂的策略，也可作为鉴定可用作人类治疗的药物的筛选工具 。

    Anti-GD2 antibodies
    47.
    发明授权
    Anti-GD2 antibodies 失效
    抗GD2抗体

    公开(公告)号：US08507657B2

    公开(公告)日：2013-08-13

    申请号：US13593057

    申请日：2012-08-23

    申请人： Nicholas C. Nicolaides ,  Philip M. Sass ,  Luigi Grasso ,  Wolfgang Ebel ,  Yuhong Zhou

    发明人： Nicholas C. Nicolaides ,  Philip M. Sass ,  Luigi Grasso ,  Wolfgang Ebel ,  Yuhong Zhou

    IPC分类号： C07K16/00 ,  C12P21/08

    CPC分类号： C07K16/3084 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

    摘要： Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.

    摘要翻译： 本文描述了特异性结合神经节苷脂GD2的抗体。 还描述了编码这种抗体的核苷酸，表达这种抗体的细胞，这种抗体的使用方法，以及使用该抗体治疗与神经节苷脂GD2相关的疾病的方法。 此外，组织培养基补充剂被描述为补充剂的使用方法。 本文描述的是白蛋白 - 神经节苷脂缀合物和用于产生这种缀合物的相应方法。 还描述了纯化或分离抗体的方法。

    Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
    48.
    发明授权
    Methods of generating high-production of antibodies from hybridomas created by in vitro immunization 有权
    从通过体外免疫产生的杂交瘤产生高产量抗体的方法

    公开(公告)号：US08445229B2

    公开(公告)日：2013-05-21

    申请号：US12786530

    申请日：2010-05-25

    申请人： Luigi Grasso ,  Shaohong Liang ,  Nicholas C. Nicolaides ,  Philip M. Sass

    发明人： Luigi Grasso ,  Shaohong Liang ,  Nicholas C. Nicolaides ,  Philip M. Sass

    IPC分类号： C12N15/01 ,  C12N15/06

    CPC分类号： C12N15/01 ,  C07K16/00 ,  C07K16/1282 ,  C07K16/243 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/73 ,  C12N15/1024

    摘要： The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.

    摘要翻译： 本发明提供了通过将骨髓瘤细胞与体外免疫的供体细胞融合而产生的杂交瘤细胞产生高亲和力抗体的高滴度的方法。 具有来自产生高亲和力抗体的杂交瘤的克隆抗体基因的杂交瘤细胞或哺乳动物表达细胞可能是错配修复缺陷，这是由于通过表达不匹配修复基因的显性负等位基因的内源性错配修复亚基的缺陷而允许杂交瘤 细胞可变性，可以通过化学方式使其变得过度，或者可能是天然错配修复缺陷。 可以通过本发明的方法制备产生抗体的高亲和力抗体和高滴度产生细胞。